Lumretuzumab

Last updated
Lumretuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target ERBB3
Clinical data
Other namesRG7116
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6512H10064N1736O2052S44
Molar mass 146916.88 g·mol−1

Lumretuzumab (INN; development code RG7116) is a humanized monoclonal antibody designed for the treatment of cancer. [1] [2]

This drug was developed by Genentech/Roche.

Related Research Articles

An international nonproprietary name (INN) is an official generic and nonproprietary name given to a pharmaceutical drug or an active ingredient. INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since 1953.

A United States Adopted Name (USAN) is a unique nonproprietary name assigned to a medication marketed in the United States. Each name is assigned by the USAN Council, which is co-sponsored by the American Medical Association (AMA), the United States Pharmacopeial Convention (USP), and the American Pharmacists Association (APhA).

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.

Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.

Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.

Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator.

<span class="mw-page-title-main">Pacritinib</span> Medication used to treat myelofibrosis

Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).

Abrilumab is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.

Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC

Lulizumab pegol is a monoclonal antibody designed for the treatment of autoimmune diseases.

Lifastuzumab vedotin is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.

Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies.

Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies.

Seribantumab is a monoclonal antibody designed for the treatment of cancer.

Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Plozalizumab is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.

Brazikumab is a human monoclonal antibody designed for the treatment of Crohn's disease. that targets IL-23.

Oleclumab is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association .
  2. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).